• Markets
    • icon
  • Companies
NTI · ASX

Neurotech International Ltd. (ASX:NTI)

AU$0.073

 0.004 (5.797%)
ASX:Live
26/07/2024 02:01:26 PM
HALO Ords GROWTH AUS All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

NTI Overview

NTI Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Very Strong

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About NTI

Website

Neurotech International Ltd.

Telephone

N/A

Address

Description

N/A

NTI Price Chart

Key Stats

Market Cap

n/a

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

%

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.0 - 0.0

Trade Value (12mth)

N/A

1 week

-11.54%

1 month

-5.48%

YTD

-9.21%

1 year

21.05%

All time high

N/A

Key Fundamentals

EPS 3 yr Growth

N/A

EBITDA Margin

N/A

Operating Cashflow

N/A

Free Cash Flow Return

N/A

ROIC

N/A

Interest Coverage

N/A

Quick Ratio

N/A

Other Data

Shares on Issue (Fully Dilluted)

N/A

HALO Sector

Healthcare

Next Company Report Date

N/A

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

N/A

Short Sell (% of issue)

N/A

NTI Announcements

Latest Announcements

Date Announcements

25 July 24

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

18 July 24

Phase II/III autism trial shows further benefits

×

Phase II/III autism trial shows further benefits

10 July 24

Significant improvement in Autism patients at 12 weeks

×

Significant improvement in Autism patients at 12 weeks

10 July 24

Investor Presentation

×

Investor Presentation

09 July 24

US FDA orphan drug designation requested for PANDAS/PANS

×

US FDA orphan drug designation requested for PANDAS/PANS

05 July 24

Appointment of Chief Medical Officer

×

Appointment of Chief Medical Officer

01 July 24

Release of Shares from Voluntary Escrow

×

Release of Shares from Voluntary Escrow

28 June 24

Expert PANDAS/PANS panel established post TGA meeting

×

Expert PANDAS/PANS panel established post TGA meeting

17 June 24

Phase I/II Autism Patients Meet 2 Years of NTI164 Treatment

×

Phase I/II Autism Patients Meet 2 Years of NTI164 Treatment

17 June 24

Investor Presentation

×

Investor Presentation

06 June 24

Further clinical benefit at 52 weeks in PANDAS/PANS patients

×

Further clinical benefit at 52 weeks in PANDAS/PANS patients

03 June 24

NTI Formalises Strategic Partnership with Fenix Innovation

×

NTI Formalises Strategic Partnership with Fenix Innovation

08 May 24

Change of Director's Interest Notice

×

Change of Director's Interest Notice

08 May 24

Notice of Change of Auditor

×

Notice of Change of Auditor

06 May 24

Rett Syndrome Phase I/II trial shows significant benefits

×

Rett Syndrome Phase I/II trial shows significant benefits

06 May 24

Investor Presentation

×

Investor Presentation

06 May 24

Investor Webinar on Rett Syndrome Clinical Trial Results

×

Investor Webinar on Rett Syndrome Clinical Trial Results

03 May 24

Trading Halt

×

Trading Halt

24 April 24

Application for quotation of securities - NTI

×

Application for quotation of securities - NTI

24 April 24

Secondary Trading Notice

×

Secondary Trading Notice

24 April 24

Notification regarding unquoted securities - NTI

×

Notification regarding unquoted securities - NTI

24 April 24

Neurotech Receives $10 Million in Placement Funds

×

Neurotech Receives $10 Million in Placement Funds

23 April 24

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

19 April 24

Board Changes

×

Board Changes

19 April 24

Proposed issue of securities - NTI

×

Proposed issue of securities - NTI

NTI Fundamentals

Per Share Records

Historical data

Forecast data

2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) AU$ Lock Lock Lock Lock -0.02 -0.00 -0.01 Lock Lock Lock
EPS (Fully Diluted) AU$ Lock Lock Lock Lock -0.02 -0.00 -0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock -36.0 68.2 -104.2 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS AU$ Lock Lock Lock Lock -0.00 -0.00 -0.01 Lock Lock Lock
FCFPS AU$ Lock Lock Lock Lock -0.00 -0.00 -0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock 32.8 -22.6 -68.4 Lock Lock Lock
     Yield % Lock Lock Lock Lock -8.9 -6.1 -19.8 Lock Lock Lock
DPS AU$ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS AU$ Lock Lock Lock Lock 0.01 0.00 0.00 Lock Lock Lock
BPS (Tangible) AU$ Lock Lock Lock Lock 0.01 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock 284.5 -63.0 121.2 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 493 697 799 Lock Lock Lock
Basic m Lock Lock Lock Lock 493 697 799 Lock Lock Lock

Financial Records

Historical data

Forecast data

2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales AU$m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock 166.5 -81.4 -84.4 Lock Lock Lock
Selling & General Expenses AU$m Lock Lock Lock Lock 7 3 9 Lock Lock Lock
Gross Income AU$m Lock Lock Lock Lock 0 -1 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock 56.3 -124.2 100.8 Lock Lock Lock
     Margin % Lock Lock Lock Lock -115.8 -1,398.8 70.7 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 216 1,499 29 Lock Lock Lock
EBITDA AU$m Lock Lock Lock Lock -7 -4 -9 Lock Lock Lock
     Growth % Lock Lock Lock Lock -526.3 47.4 -130.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock -3,611.7 -10,243.8 -151,313.1 Lock Lock Lock
Depreciation & Amortisation AU$m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT AU$m Lock Lock Lock Lock -7 -4 -9 Lock Lock Lock
     Growth % Lock Lock Lock Lock -486.3 47.3 -130.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock -3,611.7 -10,245.3 -151,342.3 Lock Lock Lock
Pretax Income AU$m Lock Lock Lock Lock -7 -4 -9 Lock Lock Lock
Income Taxes AU$m Lock Lock Lock Lock 0 -1 -1 Lock Lock Lock
Net Income AU$m Lock Lock Lock Lock -7 -3 -8 Lock Lock Lock
     Growth % Lock Lock Lock Lock -333.7 54.8 -131.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock -3,604.6 -8,787.4 -130,759.2 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow AU$m Lock Lock Lock Lock -2 -3 -6 Lock Lock Lock
Capital Expenditures AU$m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow AU$m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Financing Cash Flow AU$m Lock Lock Lock Lock 7 0 9 Lock Lock Lock
Free Cash Flow AU$m Lock Lock Lock Lock -2 -3 -6 Lock Lock Lock
     Growth % Lock Lock Lock Lock -239.3 -27.7 -113.5 Lock Lock Lock
     Margin % Lock Lock Lock Lock -11.2 -77.3 -1,060.1 Lock Lock Lock
Franking Balance AU$m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments AU$m Lock Lock Lock Lock 5 2 5 Lock Lock Lock
Total Assets AU$m Lock Lock Lock Lock 5 2 5 Lock Lock Lock
Long Term Debt AU$m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt AU$m Lock Lock Lock Lock -5 -2 -5 Lock Lock Lock
Total Liabilities AU$m Lock Lock Lock Lock 1 1 1 Lock Lock Lock
Equity AU$m Lock Lock Lock Lock 4 1 4 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 4 1 4 Lock Lock Lock
     Growth % Lock Lock Lock Lock 697.5 -63.0 177.1 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -148.4 -166.2 -146.8 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -192.4 -235.1 -196.7 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -455.5 -148.2 -334.5 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -462.2 -127.1 -289.0 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -144.1 -111.7 -234.3 Lock Lock Lock

Ratios Records

Historical data

Forecast data

2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock -4,356.5 -2,863.0 N/A Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 0.6 0.5 0.6 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -125.0 -132.5 -126.9 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 14.3 3.4 3.9 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 14.3 3.4 3.9 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 96.4 93.8 94.7 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -663.0 -498.4 -469.0 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 2.0 0.3 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock N/A 159.3 0.2 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 157.2 1,359.2 21,632.8 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -3,604.6 -10,275.4 -150,704.3 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -148.4 -194.3 -169.2 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -148.4 -166.2 -146.8 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.3 1.4 1.3 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -192.4 -235.1 -196.7 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -192.4 -235.1 -196.7 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock N/A 2.3 1,567.9 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 179.0 1,155.9 10,934.8 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 179.0 1,158.2 12,502.7 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 405.5 265.3 140,384.6 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -226.5 892.9 -127,881.9 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

%

DPSg

0.00%

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

NTI Shortsell

Frequently Asked Questions

The current share price of Neurotech International Ltd. (NTI:ASX) is AU$0.073.
The 52-week high share price for Neurotech International Ltd. (NTI:ASX) is AU$0.00.
The 52-week low share price for Neurotech International Ltd. (NTI:ASX)? is AU$0.00.
Neurotech International Ltd. (NTI:ASX) does not pay a dividend.
Neurotech International Ltd. (NTI:ASX) does not pay a dividend.
Neurotech International Ltd. (NTI:ASX) does not offer franking credits.
Neurotech International Ltd. (NTI:ASX) is classified in the Healthcare.
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.